Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ANI Pharmaceuticals Inc (ANIP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ANIP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $81.17
1 Year Target Price $81.17
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.54% | Avg. Invested days 45 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.42B USD | Price to earnings Ratio - | 1Y Target Price 81.17 |
Price to earnings Ratio - | 1Y Target Price 81.17 | ||
Volume (30-day avg) 6 | Beta 0.55 | 52 Weeks Range 52.50 - 77.00 | Updated Date 06/30/2025 |
52 Weeks Range 52.50 - 77.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -3.12% | Operating Margin (TTM) 7.61% |
Management Effectiveness
Return on Assets (TTM) 0.83% | Return on Equity (TTM) -4.57% |
Valuation
Trailing PE - | Forward PE 9.9 | Enterprise Value 1910196129 | Price to Sales(TTM) 2.1 |
Enterprise Value 1910196129 | Price to Sales(TTM) 2.1 | ||
Enterprise Value to Revenue 2.83 | Enterprise Value to EBITDA 28.57 | Shares Outstanding 21651100 | Shares Floating 15292242 |
Shares Outstanding 21651100 | Shares Floating 15292242 | ||
Percent Insiders 11.1 | Percent Institutions 101.11 |
Analyst Ratings
Rating 3 | Target Price 81.17 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ANI Pharmaceuticals Inc
Company Overview
History and Background
ANI Pharmaceuticals, Inc. was founded in 2003. It is a specialty pharmaceutical company focusing on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. ANI has grown through acquisitions and internal development, expanding its product portfolio and manufacturing capabilities.
Core Business Areas
- Generic Pharmaceuticals: Development, manufacture, and commercialization of generic prescription drugs. Includes a range of products across various therapeutic areas.
- Branded Pharmaceuticals: Development, manufacture, and commercialization of branded prescription drugs, focusing on niche and high-value markets. Includes products like Cortenema and Inderal LA.
- Contract Manufacturing: Providing contract manufacturing services to other pharmaceutical companies, leveraging its manufacturing infrastructure.
Leadership and Structure
Nikhil Lalwani serves as the President and Chief Executive Officer. The company has a board of directors overseeing strategic direction and corporate governance. The organizational structure is departmentalized, with functions for R&D, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- Cortenema: A branded rectal solution used to treat ulcerative colitis. Market share data is not publicly available in a precise figure, however, corticosteroids hold a significant market in colitis treatments. Competitors include other corticosteroid treatments and biologics, such as those by AbbVie (Humira) and Johnson & Johnson (Remicade).
- Inderal LA: A branded extended-release propranolol capsule used to treat hypertension, angina, and migraine. Market share data isn't precisely available, but beta-blockers hold a substantial share in hypertension treatments. Competitors include generic propranolol manufacturers and other beta-blocker medications.
- EEMT: EEMT products are a range of generic and branded specialty pharmaceuticals. Revenue data isn't broken down by specific product. Competitors vary by specific product, including Teva Pharmaceuticals and Mylan (now Viatris).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. Generic pharmaceuticals face price erosion, while branded pharmaceuticals benefit from patent protection. The industry is also influenced by demographic trends, healthcare reforms, and technological advancements.
Positioning
ANI Pharmaceuticals positions itself as a specialty pharmaceutical company focused on niche and high-value markets. Its competitive advantages include its integrated manufacturing capabilities, diversified product portfolio, and expertise in developing complex generics and branded drugs.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated at over $1 trillion. ANI is positioned to capture a portion of this TAM through its diverse product portfolio and strategic focus on niche markets, with the ability to adapt to market needs.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Integrated manufacturing capabilities
- Experienced management team
- Strong track record of acquisitions
- Focus on niche markets
Weaknesses
- Reliance on a few key products
- Exposure to generic price erosion
- Dependence on third-party suppliers
- Limited R&D pipeline
- High debt level
Opportunities
- Acquire complementary businesses
- Develop new branded products
- Expand into new geographic markets
- Increase contract manufacturing revenue
- Capitalize on favorable regulatory changes
Threats
- Increased competition from generic manufacturers
- Patent expirations
- Changes in healthcare regulations
- Product liability lawsuits
- Economic downturn
Competitors and Market Share
Key Competitors
- TEVA
- VTRS
- ENDP
Competitive Landscape
ANI faces stiff competition from larger generic and branded pharmaceutical companies. Its focus on niche markets and integrated manufacturing provides a competitive edge, but it must continue to innovate and acquire to maintain its position.
Major Acquisitions
Alimera Sciences' New River Pharmaceuticals, LLC
- Year: 2022
- Acquisition Price (USD millions): 16.3
- Strategic Rationale: Increased ANI's portfolio of niche branded pharma products with sustainable sales.
Oakrum Pharma, LLC
- Year: 2021
- Acquisition Price (USD millions): 210
- Strategic Rationale: This acquistion expanded ANI's portfolio of niche branded pharma products with sustainable sales and diversified manufacturing capabilities.
Growth Trajectory and Initiatives
Historical Growth: ANI Pharmaceuticals has experienced growth through acquisitions and internal development. Their growth is tied to their ability to launch new products and integrate acquired businesses effectively.
Future Projections: Future growth is dependent on successful product development, strategic acquisitions, and effective management of its existing portfolio. Analyst estimates vary based on market conditions and company performance. Refer to financial data providers.
Recent Initiatives: Recent initiatives include strategic acquisitions of products and businesses, expansion of manufacturing capabilities, and ongoing product development efforts.
Summary
ANI Pharmaceuticals is a specialty pharmaceutical company with a diversified portfolio and integrated manufacturing, allowing for both branded and generic growth. Dependence on key products and generic price erosion pose risks. Strategic acquisitions and product development are critical for future growth. The company must maintain a strong balance sheet and R&D pipeline to be competitive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- ANI Pharmaceuticals Investor Relations
- SEC Filings
- Financial News Articles
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ANI Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Baudette, MN, United States | ||
IPO Launch date 2000-05-05 | President, CEO & Director Mr. Nikhil Lalwani | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 897 | |
Full time employees 897 | |||
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.